Summary of Anteris Technologies FY Conference Call Company Overview - **Company**: Anteris Technologies (NasdaqGM:AVR) - **Industry**: Structural heart devices, specifically TAVR (Transcatheter Aortic Valve Replacement) Key Points Industry Insights - The TAVR market is valued at **$10 billion**, with only **15% patient penetration** after a decade, indicating significant room for growth [3][22] - The current TAVR products have not adequately addressed the needs of patients, leading to a large unserved market [22] Product Development and Strategy - Anteris has taken a **total disease management approach** to aortic stenosis, focusing on clinical outcomes rather than just product features [2][3] - The **DurAVR valve** is positioned as a radical redesign, the first in **20 years**, addressing issues not covered by existing products [4][5] - The company has built a strong clinical data foundation over **eight years**, leading to increased interest from physicians and strategic partners [2][5] Clinical Evidence and Innovation - Anteris claims to have more tissue science and data than any competitor, with **55,000 patients** studied, showing no calcification in high-risk populations [14][15] - The company’s **UltraResilia** tissue platform is acellular, which is believed to enhance durability compared to conventional decellularized tissues [14][15] - The design of the DurAVR valve allows for **laminar flow** and **left ventricular remodeling**, which are critical for improving patient outcomes [26][47] Market Positioning and Expectations - Anteris does not view the TAVR market as mature; instead, it sees a **rising star** opportunity due to the high percentage of untreated patients [22][23] - The company plans to launch its product **five years before FDA approval**, ensuring market readiness and penetration strategies are in place [24][25] - The focus is on **ease of use** and **clinical superiority**, which are essential for adoption by healthcare providers [25][26] Challenges and Opportunities - The company acknowledges that **education and procedural volume** are barriers to market growth, particularly in asymptomatic patients [30][31] - There is a growing recognition of the need for **multi-valve, multi-device therapy** approaches in treating heart failure, which Anteris is positioning itself to address [44][46] - The company is also focused on justifying a **premium price** for its products based on clinical benefits, which has not been effectively done by competitors [38][41] Financial Position - Anteris successfully raised **AUD 300 million**, which is expected to enhance operational stability and support clinical development [43] Future Directions - The company is actively engaging with heart failure specialists to integrate its products into broader treatment strategies, emphasizing a **polytherapeutic approach** [46][47] - Anteris aims to demonstrate significant improvements in left ventricular function, which could differentiate its offerings in the market [47] This summary encapsulates the key insights and strategic directions discussed during the Anteris Technologies FY conference call, highlighting the company's innovative approach and the potential for growth within the TAVR market.

Anteris Technologies (NasdaqGM:AVR) FY Conference Summary Company Overview - **Company**: Anteris Technologies - **Industry**: Medical Devices, specifically focusing on Transcatheter Aortic Valve Replacement (TAVR) technology Key Points and Arguments DurAVR Platform - The DurAVR platform is highlighted for its disruptive potential in the TAVR market, emphasizing a biomimetic valve design that restores the aortic valve to a more native state, promoting healthy laminar flow [3][4] - The company has developed a new class of valve, the biomimetic valve, which is more physiologically and anatomically correct compared to existing bioprosthetic designs [7][8] Clinical Performance - Anteris has achieved consistent mean gradients of 5-10 mmHg across 140 patients, indicating significant clinical performance improvements [8][10] - The product has shown a 30% reduction in left ventricular (LV) mass over six months, which is crucial for managing heart failure risks in aortic stenosis (AS) patients [19] - The patient-prosthesis mismatch (PPM) rate for DurAVR is reported at 3%, significantly lower than the 30% rate for other balloon-expandable devices, indicating better clinical outcomes [21][25] Market Dynamics - The patient demographic for TAVR has shifted from an average age of 85 to 73, necessitating different clinical requirements for younger patients [7][19] - Anteris is positioned to capture market share from competitors like Medtronic and Edwards, especially in the small annuli patient segment, where DurAVR has shown superior performance [45] Strategic Partnerships and Investments - Medtronic has made a strategic investment in Anteris, which may lead to potential co-development and co-promotion discussions, although no special rights were granted to Medtronic [39][40] - The investment is seen as a validation of Anteris's technology and market potential, especially in light of recent challenges faced by Medtronic's Evolut product [41][44] Upcoming Milestones - Anteris is preparing for significant presentations at major conferences throughout 2026, including CRT and New York Valves, where data on flow and LV remodeling will be shared [30][29] - The PARADIGM trial, which is a pivotal study for DurAVR, is expected to enroll approximately 1,000 patients, with completion anticipated in Q1 2027 [50][56] Technological Advancements - The delivery system for DurAVR is designed to be user-friendly, with advancements in balloon technology and features like commissural alignment, which are critical for adoption by physicians [76][79] - The study design for the PARADIGM trial is noted as innovative, being the first head-to-head registration trial for TAVR, which will provide comprehensive data on hemodynamic superiority and total disease management [48][49] Additional Important Insights - The company emphasizes a shift in focus from merely mechanical performance to total disease management, which includes understanding the broader implications of valve function on patient health [15][16] - The use of advanced imaging technologies like 2D and 4D MRI is becoming more prevalent in evaluating TAVR patients, which may enhance the understanding of flow dynamics post-implantation [32][36] This summary encapsulates the critical insights from the Anteris Technologies conference, highlighting the company's innovative approach, clinical advancements, and strategic positioning within the TAVR market.

Financial Data and Key Metrics Changes - The company reported a delay in FDA approval by approximately one month due to a government shutdown, but European approval was achieved on time, and the paradigm study commenced largely as scheduled [46][47] - The cost structures are expected to reflect the scale-up into the study and the pathway to commercialization, with increased investments in R&D and manufacturing [47][48] - Access to capital has improved significantly with the company's data, transitioning from a penny dreadful to a legitimate multi-billion dollar product [48][52] Business Line Data and Key Metrics Changes - The company is focused on scaling up manufacturing and ensuring high-quality product delivery, with recent facility expansions tripling capacity [15][16] - The ADAPT process is highlighted for its unique anti-calcific response and improved patient outcomes, which is critical for clinical trials and production [12][13] Market Data and Key Metrics Changes - The company has seen a significant increase in liquidity, up 1,000%, following its listing on Nasdaq, which has improved access to capital [58] - The share price has been volatile, influenced by broader market trends, particularly in the MedTech sector, which has faced challenges [59][60] Company Strategy and Development Direction - The company aims to lead in the TAVR space by focusing on innovation and quality, with a commitment to patient outcomes and a strong corporate culture [4][5][6] - The management emphasizes the importance of quality and manufacturing processes to support the investment thesis and ensure successful commercialization [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future, highlighting the importance of resilience and vision in navigating the complex healthcare landscape [7] - The company is positioned to lead the market, with competitors following its advancements in addressing aortic stenosis [44][45] Other Important Information - The company has expanded its distribution center significantly, preparing for increased volume in the upcoming months [33] - The leadership team includes experienced professionals from major global companies, enhancing the company's operational capabilities [43] Q&A Session Summary Question: What are the key milestones that support the investment thesis? - The integration of a team of leaders and experienced physicians has been crucial in achieving milestones, ensuring that the product meets market needs [76] Question: How does the company differentiate itself from competitors? - The company focuses on fundamentally different approaches to product development, aiming for significant improvements rather than incremental changes [70][71]

Financial Data and Key Metrics Changes - The company reported a slight delay in FDA approval, which was impacted by a government shutdown, but European approval was achieved on time and the paradigm study commenced largely as planned [74][75] - The cost structures are increasing as the company scales up for the study and commercialization, particularly in R&D and manufacturing, which is essential for future growth [75][76] - Access to capital has improved significantly with the company's data, transitioning from a penny dreadful to a legitimate multi-billion dollar product [76][79] Business Line Data and Key Metrics Changes - The company is focused on scaling up manufacturing and ensuring high-quality product delivery, with recent facility expansions tripling capacity [18][19] - The quality control lab is integral to ensuring that every component meets high standards before manufacturing, emphasizing patient safety and regulatory compliance [25][29] Market Data and Key Metrics Changes - The company has seen a significant increase in institutional support, with healthcare funds now investing heavily, indicating a shift in market perception [77][79] - The share price has been volatile, influenced by broader market trends rather than the company's clinical progress, with analysts generally maintaining a buy rating [86][90] Company Strategy and Development Direction - The company is committed to innovation in cardiac care, focusing on developing a valve that mimics a healthy aortic valve to reduce patient prosthesis mismatch [62][66] - The management emphasizes the importance of quality and manufacturing processes as critical to maintaining competitive advantage in the market [70][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's direction and the potential for significant impact in cardiac care, driven by a strong commitment to innovation and quality [6][72] - The competitive landscape is characterized by the company leading in scientific advancements, with competitors following its lead rather than the other way around [71][72] Other Important Information - The company has a diverse workforce, with a balanced gender ratio and a strong emphasis on cultural diversity, which is seen as beneficial for innovation and decision-making [83][84] - The transition to a U.S.-listed company has improved liquidity and access to capital, which is crucial for future growth and partnerships [85][86] Q&A Session Summary Question: What is the significance of the PPM rate in the clinical trial? - The company reported a 3% rate of patient prosthesis mismatch in their trial, significantly lower than traditional market-leading valves, which is expected to lead to better long-term patient outcomes [62][64] Question: How does the company plan to compete with other TAVR products? - Management stated that the company is leading the field in innovation and that competitors are following its advancements, indicating a strong competitive position [71][72] Question: What are the expectations for the upcoming paradigm trial? - The company is ahead of its goals for pivotal trial capacity and is well-prepared for the next phase of commercialization [19][20]